– USA, CA – MannKind Corporation (NASDAQ: MNKD) today announced the appointment of Dr. James Shannon, M.D., MRCP as the new Chairman of the Board of Directors, effective December 9, 2020, succeeding Kent Kresa who will continue to serve on the Board of Directors and as Chair of the Compensation Committee.
“Kent has done an incredible job leading the Board – as Chairman for the last four years and as Lead Independent Director for an additional five years before that,” said James Shannon. “As Al Mann’s successor, Kent helped continue Al’s mission of addressing the unmet needs of patients with diabetes and other serious illnesses. Since joining the Board in 2004, Kent has contributed significantly to the Company’s progress and he will certainly continue to do so. We are grateful for his leadership and we look forward to continuing to benefit from his experience.”
“I would like to thank Kent for our partnership during my time with MannKind,” said CEO, Michael Castagna. “He has been a great mentor, for which I will be forever thankful. Having James as Kent’s successor speaks to the caliber of our Board. James’ keen insight and leadership experience in the pharmaceutical industry will be invaluable as we continue to advance the pipeline and focus on developing innovative medicines for both endocrinology and orphan lung diseases.”
About Dr. James Shannon
Dr. Shannon served on the Board from February 2010 until April 2012 then rejoined the Board in May 2015. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior leadership positions. He served as the Chief Medical Officer for GlaxoSmithKline from 2012 -2015 and before this, served as Global Head of Pharma Development for Novartis AG based in Basel, Switzerland.
Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate and postgraduate degrees at the Queen’s University of Belfast and is a Member of the Royal College of Physicians. He currently serves on the boards of several companies including Horizon Therapeutics, Kyowa Kirin, Immodulon Therapeutics Limited, ProQR Therapeutics NV, and myTomorrows.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the-art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For more information: https://mannkindcorp.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.